A review of current clinical information, published by the National Institutes of Health, revealed that to date, no study or review has definitively shown that Hormone Replacement Therapy is an independent risk factor for the development of prostate cancer. The article further stated that, overall, the current clinical data seems to suggest that Hormone Replacement Therapy “is an appropriate therapeutic option for men with symptomatic hypogonadism (low testosterone) provided that patients continue to receive regular prostate screenings.” When you become a patient of Male Excel, our providers will evaluate your prostate health by retesting you for prostate specific antigen (PSA) at six months and at 12 months after starting HRT treatment.